{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T09:31:11Z","timestamp":1794475871998,"version":"4.9.1"},"reference-count":99,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2020,4,23]],"date-time":"2020-04-23T00:00:00Z","timestamp":1587600000000},"content-version":"unspecified","delay-in-days":22,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["HL134632"],"award-info":[{"award-number":["HL134632"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open Resp Res"],"accepted":{"date-parts":[[2020,2,29]]},"published-print":{"date-parts":[[2020,4]]},"abstract":"<jats:sec>\n                  <jats:title>Introduction<\/jats:title>\n                  <jats:p>Acetazolamide (AZM) is used for various conditions (eg, altitude sickness, sleep apnoea, glaucoma), but therapy is often limited by its side effect profile. Our objective was to estimate the risk of commonly reported side effects based on meta-analyses. We hypothesised that these risks are dose-dependent.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We queried MEDLINE\/EMBASE (Medical Literature Analysis and Retrieval System Online\/Excerpta Medica dataBASE) up until 04\/10\/2019, including any randomised placebo-controlled trial in which adults received oral AZM versus placebo reporting side effects. Eligibility assessment was performed by two independent reviewers. Data were abstracted by one reviewer who verified key entries at a second time point. For side effects reported by <jats:underline>&gt;<\/jats:underline>3 studies a pooled effect estimate was calculated, and heterogeneity assessed via I<jats:sup>2<\/jats:sup>; for outcomes reported by <jats:underline>&gt;<\/jats:underline>5 studies effect modification by total daily dose (EMbyTDD; &lt;400\u2009mg\/d, 400\u2013600\u2009mg\/d, &gt;600\u2009mg\/d) was assessed via meta-regression. For pre-specified, primary outcomes (paraesthesias, taste disturbances, polyuria and fatigue) additional subgroup analyses were performed using demographics, intervention details, laboratory changes and risk of bias.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>We included 42 studies in the meta-analyses (N<jats:sub>subjects<\/jats:sub>=1274\/1211 in AZM\/placebo groups). AZM increased the risk of all primary outcomes (p&lt;0.01, I<jats:sup>2<\/jats:sup> \u226416%\u2009and low-to-moderate quality of evidence for all)\u2014the numbers needed to harm (95% CI; n<jats:sub>Studies<\/jats:sub>) for each were: paraesthesias 2.3 (95% CI 2 to 2.7; n=39), dysgeusia 18 (95% CI 10 to 38, n=22), polyuria 17 (95% CI 9 to 49; n=22), fatigue 11 (95% CI 6 to 24; n=14). The risk for paraesthesias (beta=1.8 (95% CI 1.1\u2009to 2.9); P<jats:sub>EMbyTDD<\/jats:sub>=0.01) and dysgeusia (beta=3.1 (95% CI 1.2\u2009to 8.2); P<jats:sub>EMbyTDD<\/jats:sub>=0.02) increased with higher AZM doses; the risk of fatigue also increased with higher dose but non-significantly (beta=2.6 (95% CI 0.7 to 9.4); P<jats:sub>EMbyTDD<\/jats:sub>=0.14).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Discussion<\/jats:title>\n                  <jats:p>This comprehensive meta-analysis of low-to-moderate quality evidence defines risk of common AZM side effects and corroborates dose dependence of some side effects. These results may inform clinical decision making and support efforts to establish the lowest effective dose of AZM for various conditions.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/bmjresp-2020-000557","type":"journal-article","created":{"date-parts":[[2020,4,24]],"date-time":"2020-04-24T05:35:10Z","timestamp":1587706510000},"page":"e000557","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":115,"title":["Side effects of acetazolamide: a systematic review and meta-analysis assessing overall risk and dose dependence"],"prefix":"10.1136","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5417-9980","authenticated-orcid":false,"given":"Christopher N","family":"Schmickl","sequence":"first","affiliation":[{"name":"Department of Medicine, Division of Pulmonary, Critical Care and Sleep Medicine, University of California San Diego, La Jolla, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert L","family":"Owens","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Pulmonary, Critical Care and Sleep Medicine, University of California San Diego, La Jolla, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy E","family":"Orr","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Pulmonary, Critical Care and Sleep Medicine, University of California San Diego, La Jolla, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bradley A","family":"Edwards","sequence":"additional","affiliation":[{"name":"Sleep and Circadian Medicine Laboratory, Department of Physiology, Monash University, Clayton, Victoria, Australia"},{"name":"School of Psychological Sciences and Monash Institute of Cognitive and Clinical Neurosciences, Monash University, Clayton, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atul","family":"Malhotra","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Pulmonary, Critical Care and Sleep Medicine, University of California San Diego, La Jolla, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2020,4,23]]},"reference":[{"key":"2025083109442974000_7.1.e000557.1","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1056\/NEJM195405062501803","article-title":"Oral administration of a potent carbonic anhydrase inhibitor (diamox). I. changes in electrolyte and acid-base balance","volume":"250","author":"Leaf","year":"1954","journal-title":"N Engl J Med"},{"key":"2025083109442974000_7.1.e000557.2","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1001\/archopht.1955.00930020191004","article-title":"Long-Term acetazoleamide (diamox) administration in therapy of glaucomas","volume":"54","author":"Becker","year":"1955","journal-title":"AMA Arch Ophthalmol"},{"key":"2025083109442974000_7.1.e000557.3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM196810172791601"},{"key":"2025083109442974000_7.1.e000557.4","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.1982.00340230056012"},{"key":"2025083109442974000_7.1.e000557.5","doi-asserted-by":"publisher","DOI":"10.1378\/chest.123.5.1450"},{"key":"2025083109442974000_7.1.e000557.6","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200505-807OC"},{"key":"2025083109442974000_7.1.e000557.7","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2014.3312"},{"key":"2025083109442974000_7.1.e000557.8","doi-asserted-by":"crossref","first-page":"849","DOI":"10.2174\/156802607780636735","article-title":"The development of topically acting carbonic anhydrase inhibitors as anti-glaucoma agents","volume":"7","author":"Mincione","year":"2007","journal-title":"Curr Top Med Chem"},{"key":"2025083109442974000_7.1.e000557.9","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.1980.01020031041005"},{"key":"2025083109442974000_7.1.e000557.10","first-page":"Cd009761","article-title":"Interventions for preventing high altitude illness: Part 1. Commonly-used classes of drugs","volume":"6","author":"Nieto Estrada","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"2025083109442974000_7.1.e000557.11","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.e6779","article-title":"Identifying the lowest effective dose of acetazolamide for the prophylaxis of acute mountain sickness: systematic review and meta-analysis","volume":"345","author":"Low","year":"2012","journal-title":"BMJ"},{"key":"2025083109442974000_7.1.e000557.12","doi-asserted-by":"publisher","DOI":"10.1089\/ham.2011.1084"},{"key":"2025083109442974000_7.1.e000557.13","first-page":"Cd009567","article-title":"Interventions for treating acute high altitude illness","volume":"6","author":"Simancas-Racines","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"2025083109442974000_7.1.e000557.14","doi-asserted-by":"publisher","DOI":"10.1113\/jphysiol.2011.223925"},{"key":"2025083109442974000_7.1.e000557.15","doi-asserted-by":"publisher","DOI":"10.1089\/152702903321488979"},{"key":"2025083109442974000_7.1.e000557.16","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.1977.04450080088009"},{"key":"2025083109442974000_7.1.e000557.17","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1097\/01.mjt.0000182359.63457.01","article-title":"Effects of the selective cyclooxygenase-2 inhibitor analgesic celecoxib on renal carbonic anhydrase enzyme activity: a randomized, controlled trial","volume":"13","author":"Alper","year":"2006","journal-title":"Am J Ther"},{"key":"2025083109442974000_7.1.e000557.18","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.98.12061242"},{"key":"2025083109442974000_7.1.e000557.19","doi-asserted-by":"publisher","DOI":"10.1002\/j.1552-4604.1989.tb03340.x"},{"key":"2025083109442974000_7.1.e000557.20","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1089\/jop.1999.15.97","article-title":"Relationship between acetazolamide blood concentration and its side effects in glaucomatous patients","volume":"15","author":"Inatani","year":"1999","journal-title":"J Ocul Pharmacol Ther"},{"key":"2025083109442974000_7.1.e000557.21","doi-asserted-by":"publisher","DOI":"10.1007\/s002280050422"},{"key":"2025083109442974000_7.1.e000557.22","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.b2535"},{"key":"2025083109442974000_7.1.e000557.23","first-page":"5100","article-title":"Acetozolamide and highland-vitamin-tablet for improving the recovery after exhaustion exercise at high altitude","volume":"8","author":"Cui","year":"2004","journal-title":"Chinese Journal of Clinical Rehabilitation"},{"key":"2025083109442974000_7.1.e000557.24","first-page":"621","article-title":"Investigating the effect of two doses of acetazolamide, as a precursor for relief of referral pain, after laparoscopic cholecystectomy with carbon dioxide gas, and comparing it with control group","volume":"36","author":"Sajedi","year":"2018","journal-title":"Journal of Isfahan Medical School"},{"key":"2025083109442974000_7.1.e000557.25","doi-asserted-by":"crossref","unstructured":"Higgins JPT , Green S . Cochrane Handbook for systematic reviews of interventions version 5.1.0, 2019. www.handbook.cochrane.org","DOI":"10.1002\/9781119536604"},{"key":"2025083109442974000_7.1.e000557.26","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2288-7-5","article-title":"Inclusion of zero total event trials in meta-analyses maintains analytic consistency and incorporates all available data","volume":"7","author":"Friedrich","year":"2007","journal-title":"BMC Med Res Methodol"},{"key":"2025083109442974000_7.1.e000557.27","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.317.7168.1309"},{"key":"2025083109442974000_7.1.e000557.28","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.327.7414.557"},{"key":"2025083109442974000_7.1.e000557.29","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1097\/WNO.0000000000000322","article-title":"Safety and tolerability of acetazolamide in the idiopathic intracranial hypertension treatment trial","volume":"36","author":"ten Hove","year":"2016","journal-title":"J Neuroophthalmol"},{"key":"2025083109442974000_7.1.e000557.30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.resp.2017.07.005","article-title":"Acetazolamide and N-acetylcysteine in the treatment of chronic mountain sickness (Monge's disease)","volume":"246","author":"Sharma","year":"2017","journal-title":"Respir Physiol Neurobiol"},{"key":"2025083109442974000_7.1.e000557.31","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1007\/s11255-017-1566-2","article-title":"A pilot randomized study on use of oral acetazolamide in patients with refractory dysuria","volume":"49","author":"Hamidi","year":"2017","journal-title":"Int Urol Nephrol"},{"key":"2025083109442974000_7.1.e000557.32","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1089\/lap.2014.0507","article-title":"Comparison of preoperative oral acetazolamide and intraperitoneal normal saline irrigation for reduction of postoperative pain after laparoscopic cholecystectomy","volume":"25","author":"Bala","year":"2015","journal-title":"J Laparoendosc Adv Surg Tech A"},{"key":"2025083109442974000_7.1.e000557.33","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/eht540"},{"key":"2025083109442974000_7.1.e000557.34","doi-asserted-by":"publisher","DOI":"10.1089\/ham.2012.1099"},{"key":"2025083109442974000_7.1.e000557.35","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1111\/crj.12025","article-title":"Acetazolamide improves oxygenation in patients with respiratory failure and metabolic alkalosis","volume":"7","author":"Gulsvik","year":"2013","journal-title":"Clin Respir J"},{"key":"2025083109442974000_7.1.e000557.36","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.ntt.2012.12.003","article-title":"Effects of acetazolamide on cognitive performance during high-altitude exposure","volume":"35","author":"Wang","year":"2013","journal-title":"Neurotoxicol Teratol"},{"key":"2025083109442974000_7.1.e000557.37","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2012.94847"},{"key":"2025083109442974000_7.1.e000557.38","doi-asserted-by":"publisher","DOI":"10.1378\/chest.11-0375"},{"key":"2025083109442974000_7.1.e000557.39","doi-asserted-by":"publisher","DOI":"10.1089\/ham.2008.1029"},{"key":"2025083109442974000_7.1.e000557.40","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200802-196OC"},{"key":"2025083109442974000_7.1.e000557.41","doi-asserted-by":"publisher","DOI":"10.1580\/1080-6032-17.2.87"},{"key":"2025083109442974000_7.1.e000557.42","doi-asserted-by":"publisher","DOI":"10.1089\/ham.2006.7.17"},{"key":"2025083109442974000_7.1.e000557.43","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200507-1035OC"},{"key":"2025083109442974000_7.1.e000557.44","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.165.3.296"},{"key":"2025083109442974000_7.1.e000557.45","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.38043.501690.7C"},{"key":"2025083109442974000_7.1.e000557.46","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.03.00113102"},{"key":"2025083109442974000_7.1.e000557.47","doi-asserted-by":"publisher","DOI":"10.1086\/342299"},{"key":"2025083109442974000_7.1.e000557.48","doi-asserted-by":"publisher","DOI":"10.1007\/PL00007866"},{"key":"2025083109442974000_7.1.e000557.49","doi-asserted-by":"publisher","DOI":"10.1007\/s100720070069"},{"key":"2025083109442974000_7.1.e000557.50","doi-asserted-by":"publisher","DOI":"10.1007\/s004170050175"},{"key":"2025083109442974000_7.1.e000557.51","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.1997.01100160411003"},{"key":"2025083109442974000_7.1.e000557.52","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0161-6420(96)30567-8","article-title":"A randomized, masked, cross-over trial of acetazolamide for cystoid macular edema in patients with uveitis","volume":"103","author":"Whitcup","year":"1996","journal-title":"Ophthalmology"},{"key":"2025083109442974000_7.1.e000557.53","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1183\/09031936.94.07050850","article-title":"Effects of chlormadinone acetate, acetazolamide and oxygen on awake and asleep gas exchange in patients with chronic obstructive pulmonary disease (COPD)","volume":"7","author":"Vos","year":"1994","journal-title":"Eur Respir J"},{"key":"2025083109442974000_7.1.e000557.54","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.78.1.4"},{"key":"2025083109442974000_7.1.e000557.55","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.77.3.136"},{"key":"2025083109442974000_7.1.e000557.56","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-116-6-461"},{"key":"2025083109442974000_7.1.e000557.57","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.1989.01070020519031"},{"key":"2025083109442974000_7.1.e000557.58","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.73.8.612"},{"key":"2025083109442974000_7.1.e000557.59","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1093\/sleep\/11.5.463","article-title":"Role of protriptyline and acetazolamide in the sleep apnea\/hypopnea syndrome","volume":"11","author":"Whyte","year":"1988","journal-title":"Sleep"},{"key":"2025083109442974000_7.1.e000557.60","first-page":"110","article-title":"[Acetazolamide in hypercapnic chronic obstructive lung disease--a renaissance?]","volume":"113","author":"H\u00e4cki","year":"1983","journal-title":"Schweiz Med Wochenschr"},{"key":"2025083109442974000_7.1.e000557.61","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1982.03330030034021"},{"key":"2025083109442974000_7.1.e000557.62","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.283.6295.811"},{"key":"2025083109442974000_7.1.e000557.63","first-page":"180","article-title":"Acetazolamide in control of acute mountain sickness","volume":"1","year":"1981","journal-title":"Lancet"},{"key":"2025083109442974000_7.1.e000557.64","doi-asserted-by":"crossref","first-page":"e00203","DOI":"10.1002\/prp2.203","article-title":"Benzolamide improves oxygenation and reduces acute mountain sickness during a high-altitude TREK and has fewer side effects than acetazolamide at sea level","volume":"4","author":"Collier","year":"2016","journal-title":"Pharmacol Res Perspect"},{"key":"2025083109442974000_7.1.e000557.65","doi-asserted-by":"publisher","DOI":"10.1580\/0953-9859-5.3.312"},{"key":"2025083109442974000_7.1.e000557.66","doi-asserted-by":"crossref","unstructured":"Rosenbaek JB , Pedersen EB , Bech JN . The effect of sodium nitrite infusion on renal function, brachial and central blood pressure during enzyme inhibition by allopurinol, enalapril or acetazolamide in healthy subjects: a randomized, double-blinded, placebo-controlled, crossover study. BMC Nephrol 2018;19.doi:10.1186\/s12882-018-1035-x","DOI":"10.1186\/s12882-018-1035-x"},{"key":"2025083109442974000_7.1.e000557.67","first-page":"1122","article-title":"[Prevention of acute mountain sickness using acetazolamide]","volume":"112","author":"Utz","year":"1970","journal-title":"Munch Med Wochenschr"},{"key":"2025083109442974000_7.1.e000557.68","first-page":"541","article-title":"Acetazolamide and dexamethasone in the prevention of acute mountain sickness","volume":"148","author":"Zell","year":"1988","journal-title":"West J Med"},{"key":"2025083109442974000_7.1.e000557.69","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.wem.2014.08.017","article-title":"The effect of acetazolamide on saccadic latency at 3459 meters","volume":"26","author":"Faull","year":"2015","journal-title":"Wilderness Environ Med"},{"key":"2025083109442974000_7.1.e000557.70","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.wem.2014.04.003","article-title":"Exercise limitation of acetazolamide at altitude (3459 M)","volume":"25","author":"Bradwell","year":"2014","journal-title":"Wilderness Environ Med"},{"key":"2025083109442974000_7.1.e000557.71","doi-asserted-by":"publisher","DOI":"10.1007\/s00421-009-1042-5"},{"key":"2025083109442974000_7.1.e000557.72","doi-asserted-by":"publisher","DOI":"10.1152\/japplphysiol.00180.2007"},{"key":"2025083109442974000_7.1.e000557.73","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1042\/CS20050233","article-title":"Effect of acetazolamide on leg endurance exercise at sea level and simulated altitude","volume":"110","author":"Fulco","year":"2006","journal-title":"Clin Sci"},{"key":"2025083109442974000_7.1.e000557.74","doi-asserted-by":"publisher","DOI":"10.1152\/japplphysiol.00746.2001"},{"key":"2025083109442974000_7.1.e000557.75","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-4598(199712)20:12<1541::AID-MUS9>3.0.CO;2-8"},{"key":"2025083109442974000_7.1.e000557.76","doi-asserted-by":"publisher","DOI":"10.1007\/BF02343071"},{"key":"2025083109442974000_7.1.e000557.77","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1089\/152702902753639612","article-title":"Leukonychia following high altitude exposure","volume":"3","author":"Burtscher","year":"2002","journal-title":"High Alt Med Biol"},{"key":"2025083109442974000_7.1.e000557.78","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1016\/S0140-6736(81)92013-4","article-title":"Acetazolamide in the mountains","volume":"317","author":"Bradwell","year":"1981","journal-title":"The Lancet"},{"key":"2025083109442974000_7.1.e000557.79","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1093\/sleep\/11.4.354","article-title":"Altitude insomnia: studies during an expedition to the Himalayas","volume":"11","author":"Nicholson","year":"1988","journal-title":"Sleep"},{"key":"2025083109442974000_7.1.e000557.80","first-page":"1","article-title":"Effects of acetazolamide on physiologic and subjective responses of men to 14,000 feet. SAM-TR-67-81","author":"Kronenberg","year":"1967","journal-title":"Tech Rep SAM-TR"},{"key":"2025083109442974000_7.1.e000557.81","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1212\/WNL.0000000000002416","article-title":"Randomized, placebo-controlled trials of dichlorphenamide in periodic paralysis","volume":"86","author":"Sansone","year":"2016","journal-title":"Neurology"},{"key":"2025083109442974000_7.1.e000557.82","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1055\/s-0043-125352","article-title":"Guideline myotonic dystrophies, Non-Dystrophic myotonias and periodic paralyses","volume":"45","author":"Schneider-Gold","year":"2018","journal-title":"Aktuelle Neurologie"},{"key":"2025083109442974000_7.1.e000557.83","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(76)91677-9"},{"key":"2025083109442974000_7.1.e000557.84","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i5075"},{"key":"2025083109442974000_7.1.e000557.85","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.f7668","article-title":"Quality of reporting in systematic reviews of adverse events: systematic review","volume":"348","author":"Zorzela","year":"2013","journal-title":"BMJ"},{"key":"2025083109442974000_7.1.e000557.86","doi-asserted-by":"publisher","DOI":"10.1089\/152702904322963672"},{"key":"2025083109442974000_7.1.e000557.87","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehu424"},{"key":"2025083109442974000_7.1.e000557.88","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1819.1995.tb01858.x"},{"key":"2025083109442974000_7.1.e000557.89","doi-asserted-by":"publisher","DOI":"10.1513\/AnnalsATS.201306-201OC"},{"key":"2025083109442974000_7.1.e000557.90","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1111\/j.1755-3768.1984.tb05801.x","article-title":"Zinc therapy of ACETAZOLAMIDE-INDUCED side-effects","volume":"62","author":"Dahl","year":"1984","journal-title":"Acta Ophthalmol"},{"key":"2025083109442974000_7.1.e000557.91","doi-asserted-by":"publisher","DOI":"10.1016\/j.smrv.2013.03.002"},{"key":"2025083109442974000_7.1.e000557.92","doi-asserted-by":"publisher","DOI":"10.1378\/chest.87.5.619"},{"key":"2025083109442974000_7.1.e000557.93","doi-asserted-by":"publisher","DOI":"10.1517\/14740338.2014.897328"},{"key":"2025083109442974000_7.1.e000557.94","first-page":"1086","article-title":"Acetazolamide use in severe chronic obstructive pulmonary disease. pros and cons","volume":"14","author":"Adamson","year":"2017","journal-title":"Ann Am Thorac Soc"},{"key":"2025083109442974000_7.1.e000557.95","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1111\/bcp.13499","article-title":"Metabolic acidosis and anaemia associated with dorzolamide in a patient with impaired renal function","volume":"84","author":"Hoffmanov\u00e1","year":"2018","journal-title":"Br J Clin Pharmacol"},{"key":"2025083109442974000_7.1.e000557.96","doi-asserted-by":"publisher","DOI":"10.14814\/phy2.12484"},{"key":"2025083109442974000_7.1.e000557.97","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/S0002-9394(14)75247-X","article-title":"Patient tolerance to carbonic anhydrase inhibitors","volume":"85","author":"Lichter","year":"1978","journal-title":"Am J Ophthalmol"},{"key":"2025083109442974000_7.1.e000557.98","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/S0161-6420(81)35040-4","article-title":"Reducing side effects of carbonic anhydrase inhibitors","volume":"88","author":"Lichter","year":"1981","journal-title":"Ophthalmology"},{"key":"2025083109442974000_7.1.e000557.99","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/S0022-3565(25)26470-9","article-title":"The relation between enzyme inhibition and physiological response in the carbonic anhydrase system","volume":"139","author":"Maren","year":"1963","journal-title":"J Pharmacol Exp Ther"}],"container-title":["BMJ Open Respiratory Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjresp-2020-000557","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,31]],"date-time":"2025-08-31T16:44:42Z","timestamp":1756658682000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopenrespres.bmj.com\/lookup\/doi\/10.1136\/bmjresp-2020-000557"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4]]},"references-count":99,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,4,23]]},"published-print":{"date-parts":[[2020,4]]}},"alternative-id":["10.1136\/bmjresp-2020-000557"],"URL":"https:\/\/doi.org\/10.1136\/bmjresp-2020-000557","relation":{},"ISSN":["2052-4439"],"issn-type":[{"value":"2052-4439","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4]]}}}